Early-Stage Lung Cancer

3

Review clinical trials related to Early-Stage Lung Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Prospective Phase II Clinical Study of Stereotactic Body Proton Therapy (SBPT) for Lung Cancer

This study included patients with early-stage lung cancer cT1-3N0M0, stage IA-IIB (American Joint Committee on Cancer eighth edition staging, AJCC 8th ) who were inoperable or refused surgery. They were divided into peripheral type and central type according to the tumor location and received radical Stereotactic Body Proton Therapy (SBPT) for Early-Stage Non-Small Cell Lung Cancer. The prescribed dose for patients with peripheral lung cancer is 48-60Gray(Gy) (Relative Biological Effectiveness, RBE)/4-6 fractions, and for patients with central lung cancer, the prescribed dose is 50-70Gy(RBE)/10-15 fractions. After treatment, follow-up visits will be conducted to observe short-term and long-term efficacy, adverse reactions and patient quality of life.

Participants needed: 65
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Guangzhou Concord Cancer CenterUpdated: May 22, 2026Locations: 1
Eligibility criteria

.Lung cancer confirmed by histology and/or cytology; and in the absence of patho... [+8]

Patients with other malignant tumors. [+5]

Status: Not yet recruiting

Application of Electromagnetic Navigation System in Pulmonary Nodule Localization

This study aims to design and conduct a multicenter, prospective, randomized controlled post-market clinical trial to validate the clinical efficacy of high-precision electromagnetic navigation technology.

Participants needed: 400
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: Shanghai Pulmonary Hospital, Shanghai, ChinaUpdated: May 19, 2026Locations: 1
Eligibility criteria

Age 18-80 years, regardless of gender; [+4]

Not suitable for video-assisted thoracoscopic surgery; [+4]

Status: Recruiting

Septum-guided Segmentectomy for Deep Early-stage Lung Cancer (SGS2512)

The purpose of this study is to evaluate the safety and effectiveness of a specialized surgical technique called "Septum-guided Segmentectomy" for treating early-stage lung cancer located deep within the lung tissue.Standard surgery for lung cancer often involves removing an entire lung lobe (lobectomy), which can significantly reduce a patient's breathing capacity. For small tumors, removing only a segment of the lung (segmentectomy) can preserve more healthy tissue. However, for tumors located deep in the lung, traditional segmentectomy is technically challenging and risks leaving cancer cells behind.In this study, surgeons will use the natural anatomical boundaries-the intersegmental veins and their surrounding thin membranes (septa)-as a guide to precisely remove the target lung segment. This "septum-guided" approach aims to ensure the cancer is completely removed while maximizing the preservation of healthy lung function.Participants will be followed for 3 years after surgery to monitor for cancer recurrence and assess their long-term recovery.

Participants needed: 89
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: Shanghai Chest HospitalUpdated: May 4, 2026Locations: 1
Eligibility criteria

Age 18-80 years [+7]

Multiple pulmonary nodules or evidence of distant metastasis [+5]